Keyphrases
Intrahepatic Bile Duct
100%
Immune-related Adverse Events
100%
Advanced Hepatocellular Carcinoma
100%
Bile Duct Injury
100%
Spontaneous Intestinal Perforation
100%
Immune Checkpoint Inhibitor Treatment
100%
Lenvatinib
100%
Metastasis
60%
Hepatic Angiosarcoma
50%
Autopsy Cases
50%
Transcatheter Arterial Embolization
50%
Steroid Treatment
40%
Small Intestine
40%
Ischemic Changes
32%
Liver Tumor
25%
Cancer Types
20%
Serious Condition
20%
Cytokeratin 7
20%
Sorafenib
20%
Vascular Endothelial Growth Factor Receptor (VEGFR)
20%
Hepatocellular Carcinoma
20%
CD-8
20%
Antitumor Effect
20%
Partial Necrosis
20%
Line Standard
20%
Perforation
20%
Immune Checkpoint Inhibitors
20%
Fibroblast Growth Factor Receptor 1 (FGFR1)
20%
Immunostaining
20%
Immunosuppressive Therapy
20%
Prompt Diagnosis
20%
Japanese Workers
12%
Aged 80 Years and over
12%
Ischemia
12%
Tumor Necrosis
12%
Tumor Cell Necrosis
12%
Autopsy Findings
12%
Hemostasis
12%
Treatment Optimization
12%
Rerupture
12%
Embolization
12%
Embolic Agent
12%
Intra-abdominal Hemorrhage
12%
Angiosarcoma
12%
Old Japanese
12%
Medicine and Dentistry
Intrahepatic Bile Duct
100%
Immune-Related Adverse Events
100%
Hepatocellular Carcinoma
100%
Lenvatinib
100%
Small Intestine
100%
Bile Duct Injury
100%
Immune Checkpoint Inhibitor
100%
Metastatic Carcinoma
60%
Arterial Embolization
50%
Angiosarcoma
50%
Steroid Treatment
40%
Vasculotropin Receptor
20%
Immunosuppressive Treatment
20%
Fibroblast Growth Factor Receptor
20%
Malignant Neoplasm
20%
Sorafenib
20%
Kinase
20%
CD8 Antigen
20%
Neoplasm
20%
Immunohistochemistry
20%
Liver Tumor
20%
Keratin 7
20%
Necrosis
20%
Embolization
10%
Interlobular Arteries
10%
Abdominal Bleeding
10%
Tumor Necrosis
10%
Blood Stasis
10%
Tumor Cell
10%
Cell Death
10%
Ischemia
10%